Abstract
In the 2019 global consensus position statement on testosterone,1 the expert panel stated that the only evidence-based indication for testosterone use in women was for the treatment of hypoactive sexual desire disorder (HSDD) in naturally or surgically postmenopausal women. This recommendation was largely based upon a systematic review and meta-analysis of randomized, placebo-controlled trial data assessing the efficacy and safety of testosterone on sexual function in women.2 Testosterone, when administered to achieve doses that approximate physiological levels in premenopausal women, was determined to have beneficial effects on sexual function in postmenopausal women, including increases in frequency of satisfactory sexual events, pleasure, arousal, orgasm, and responsiveness with concomitant decrease in distress.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
